[go: up one dir, main page]

WO2010102778A3 - Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren - Google Patents

Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren Download PDF

Info

Publication number
WO2010102778A3
WO2010102778A3 PCT/EP2010/001448 EP2010001448W WO2010102778A3 WO 2010102778 A3 WO2010102778 A3 WO 2010102778A3 EP 2010001448 W EP2010001448 W EP 2010001448W WO 2010102778 A3 WO2010102778 A3 WO 2010102778A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminoisoxazolopyridines
substituted
kcnq2
modulators
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/001448
Other languages
English (en)
French (fr)
Other versions
WO2010102778A2 (de
Inventor
Sven KÜHNER
Gregor Bahrenberg
Wolfgang Schröder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to BRPI1009428A priority Critical patent/BRPI1009428A2/pt
Priority to EP10707838A priority patent/EP2406265A2/de
Priority to AU2010223555A priority patent/AU2010223555A1/en
Priority to JP2011553338A priority patent/JP2012520246A/ja
Priority to MX2011008825A priority patent/MX2011008825A/es
Priority to CA2754934A priority patent/CA2754934A1/en
Publication of WO2010102778A2 publication Critical patent/WO2010102778A2/de
Publication of WO2010102778A3 publication Critical patent/WO2010102778A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Die Erfindung betrifft substituierte 3-Aminoisoxazolopyridine, Verfahren zu ihrer Herstellung, Arzneimittel enthaltend diese Verbindungen sowie die Verwendung dieser Verbindungen zur Herstellung von Arzneimitteln.
PCT/EP2010/001448 2009-03-10 2010-03-09 Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren Ceased WO2010102778A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI1009428A BRPI1009428A2 (pt) 2009-03-10 2010-03-09 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
EP10707838A EP2406265A2 (de) 2009-03-10 2010-03-09 Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
AU2010223555A AU2010223555A1 (en) 2009-03-10 2010-03-09 Substituted 3-aminoisoxazolopyridines as KCNQ2/3 modulators
JP2011553338A JP2012520246A (ja) 2009-03-10 2010-03-09 Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
MX2011008825A MX2011008825A (es) 2009-03-10 2010-03-09 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
CA2754934A CA2754934A1 (en) 2009-03-10 2010-03-09 Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09003430.7 2009-03-10
EP09003430 2009-03-10

Publications (2)

Publication Number Publication Date
WO2010102778A2 WO2010102778A2 (de) 2010-09-16
WO2010102778A3 true WO2010102778A3 (de) 2010-12-16

Family

ID=41024842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/001448 Ceased WO2010102778A2 (de) 2009-03-10 2010-03-09 Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren

Country Status (8)

Country Link
US (1) US20100234419A1 (de)
EP (1) EP2406265A2 (de)
JP (1) JP2012520246A (de)
AU (1) AU2010223555A1 (de)
BR (1) BRPI1009428A2 (de)
CA (1) CA2754934A1 (de)
MX (1) MX2011008825A (de)
WO (1) WO2010102778A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
US8653102B2 (en) 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators
CA2805932A1 (en) 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
MX342119B (es) 2010-08-27 2016-09-14 Grünenthal Gmbh * 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EP2611780A1 (de) 2010-09-01 2013-07-10 Grünenthal GmbH Substituierte 1-oxo-dihydroisochinolin -3-carboxamide als kcnq2/3 modulatoren
KR20170034439A (ko) * 2014-08-13 2017-03-28 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
WO2017034420A1 (en) 2015-08-27 2017-03-02 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CN110627714A (zh) * 2019-10-16 2019-12-31 安庆博曼生物技术有限公司 3-氟-2-三氟甲基异烟酸的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074388A1 (en) * 2001-03-19 2002-09-26 Icagen, Inc. Bisarylamines as potassium channel openers
WO2006122800A1 (de) * 2005-05-18 2006-11-23 Grünenthal GmbH Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
WO2007030582A2 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
WO2008011110A2 (en) * 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
AU2007275653B2 (en) 2006-07-20 2010-12-23 Amgen Inc. Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074388A1 (en) * 2001-03-19 2002-09-26 Icagen, Inc. Bisarylamines as potassium channel openers
WO2006122800A1 (de) * 2005-05-18 2006-11-23 Grünenthal GmbH Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
WO2006122799A1 (de) * 2005-05-18 2006-11-23 Grünenthal GmbH Benzo (d) isoxazol-3-yl-amin- verbindungen und deren verwendung als vanilloid-rezeptor liganden
WO2007030582A2 (en) * 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
WO2008011110A2 (en) * 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use

Also Published As

Publication number Publication date
AU2010223555A1 (en) 2011-11-03
BRPI1009428A2 (pt) 2016-03-01
JP2012520246A (ja) 2012-09-06
US20100234419A1 (en) 2010-09-16
MX2011008825A (es) 2011-09-21
CA2754934A1 (en) 2010-09-16
WO2010102778A2 (de) 2010-09-16
EP2406265A2 (de) 2012-01-18

Similar Documents

Publication Publication Date Title
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
ZA201107806B (en) Organisms for the production of 1,3-butanediol
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
WO2009140624A3 (en) Glucokinase activators
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
IL219530A (en) Converted 4-aminocyclohexane compounds, drugs containing these compounds and their use in the preparation of drugs
WO2007093627A3 (de) Biozide zusammensetzung
EP2130909A4 (de) Verfahren zur zahnherstellung und damit hergestellter zahn
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2012136898A3 (en) Novel cutinases, their production and uses
MY158910A (en) Surface modified silicic acid semi-gels
WO2009120192A3 (en) Processes for the preparation of benzo-fused dioxin derivatives
WO2008065282A3 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010079045A3 (en) Crystalline salt forms of flibanserine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707838

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010707838

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008825

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2754934

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011553338

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010223555

Country of ref document: AU

Date of ref document: 20100309

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1009428

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1009428

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110909